论文部分内容阅读
1963年,Fleckenstein 对当时新合成的冠状动脉扩张药双苯丙胺(Prenylamine)和戊脉安(Verapamil)进行了心抑制作用机理的研究。发现其抑制作用和细胞外液Ca~(++)减低时的作用(Ca~(++)依赖性高能磷酸化合物利用减少,心收缩抑制,心肌耗氧量减少)相类似。当投与 Ca~(++)、交感神经兴奋药和强心配糖体后,这种抑制作用随着心收缩时 Ca~(++)供给的改善而消失。Fleckenstein 将在心肌和平滑肌内,对 Na~+依赖性活动电位
In 1963, Fleckenstein studied the cardiac inhibition mechanism of newly synthesized coronary dilation agents Prenylamine and Verapamil. The inhibitory effect was found to be similar to the decrease of extracellular Ca ~ (++) (Ca ~ (++) dependent reduction of high-energy phosphate compounds, inhibition of cardiac contractility and decrease of myocardial oxygen consumption). After administration of Ca ~ (++), sympathetic stimulants and cardiac glycosides, this inhibitory effect disappeared with the improvement of Ca ~ (++) supply during cardiac contractility. Fleckenstein will have Na ~ + -dependent activity potential in myocardium and smooth muscle